Clinical trials for Cervical / Vulvar / Vaginal cancer

51 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT05768139 #2023-000442-41

[PIKALO-1] Première étude chez l'homme du STX-478 en monothérapie et en association avec d'autres agents antinéoplasiques chez des participants atteints de tumeurs solides avancées

Cohortes autres tumeurs solides

Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses Squamous cell carcinoma HR Positive Locally Advanced Metastatic PIK3CA 1 2 3 or more

6 recruiting sites

Eli Lilly et compagnie

Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Acute leukemia Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT07403721

Étude de phase 1/1b évaluant la sécurité, la tolérance et la pharmacocinétique de l'AMG 436 en monothérapie et en association avec d'autres thérapies chez des participants atteints de tumeurs solides présentant une instabilité microsatellitaire élevée (MSI-H)/un déficit de réparation des mésappariements (dMMR).

Locally Advanced Metastatic Metastatic Castration-resistant MSI/dMMR 1 2 3 or more

Systemic Treatment-Naive

1 recruiting site

Amgen

Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT05856981 #2022-502757-34-00

Étude de phase 1 évaluant la sécurité et la pharmacocinétique de l'ADU-1805 dans les tumeurs solides avancées

Escalade de dose

Locally Advanced Metastatic 1 2 3 or more

Systemic Treatment-Naive

2 recruiting sites

Sairopa BV

Phase 1 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT04777994

Étude avec l'ABBV-CLS-484 chez des participants atteints de tumeurs localement avancées ou métastatiques

Dose d'expansion cohorte combinaison avec inhibiteur PD-1 tumeurs MSI-H

Locally Advanced Metastatic MSI/dMMR 1 2 3 or more Immunotherapy

Systemic Treatment-Naive

4 recruiting sites

Calico Life Sciences LLC

Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT06551142 #2024-513663-10

[EMBOLD PanTumor-101] Étude du GSK5764227 chez des participants atteints de tumeurs solides avancées

Phase 1a

Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more

Systemic Treatment-Naive

3 recruiting sites

GlaxoSmithKline

Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07094204 #2025-522082-29-00

Étude visant à déterminer la dose appropriée d'ASP5834 chez les adultes atteints de tumeurs solides

Escalade de dose monothérapie

Locally Advanced Metastatic Metastatic Castration-resistant Other KRAS KRAS G12C KRAS G12D KRAS non G12C 1 2 3 or more

Systemic Treatment-Naive

4 recruiting sites

Astellas Pharma Développement mondial, Inc.

Phase 1 Breast cancer Prostate cancer Kidney cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07094204 #2025-522082-29-00

Étude visant à déterminer la dose appropriée d'ASP5834 chez les adultes atteints de tumeurs solides

Cohorte extension de dose autres tumeurs

Locally Advanced Metastatic Other KRAS KRAS G12C KRAS G12D KRAS non G12C 1 2 3 or more

Systemic Treatment-Naive

4 recruiting sites

Astellas Pharma Développement mondial, Inc.

Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06026410

KO-2806 Monothérapie et thérapies combinées dans les tumeurs solides avancées

Bras 1 (Tumeurs solides avancées avec altération du gène RAS)

Locally Advanced Metastatic Other KRAS HRAS KRAS G12C KRAS G12D KRAS non G12C NRAS 1 2 3 or more

Systemic Treatment-Naive

3 recruiting sites

Kura Oncologie, Inc.

Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06179160 #2023-507091-47-00

Étude visant à évaluer l'INCB161734 chez des participants atteints de tumeurs solides avancées ou métastatiques présentant une mutation KRAS G12D

Locally Advanced Metastatic KRAS G12D 1 2 3 or more

Systemic Treatment-Naive

3 recruiting sites

Incyte Corporation

Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07094113

AMG 410 seul et en association avec d'autres agents chez des participants atteints de tumeurs solides avancées ou métastatiques présentant une altération du gène KRAS

Parties 1, 2 et 3a

Locally Advanced Metastatic Other KRAS KRAS G12C KRAS G12D KRAS non G12C 1 2 3 or more

Systemic Treatment-Naive

2 recruiting sites

Amgen